As of 2025-06-10, the Intrinsic Value of Zealand Pharma A/S (ZEAL.CO) is (313.29) DKK. This ZEAL.CO valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 466.00 DKK, the upside of Zealand Pharma A/S is -167.20%.
The range of the Intrinsic Value is (1,851.30) - (175.72) DKK
Based on its market price of 466.00 DKK and our intrinsic valuation, Zealand Pharma A/S (ZEAL.CO) is overvalued by 167.20%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (1,851.30) - (175.72) | (313.29) | -167.2% |
| DCF (Growth 10y) | (178.30) - (1,693.63) | (303.95) | -165.2% |
| DCF (EBITDA 5y) | (65.06) - (104.54) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (92.83) - (139.29) | (1,234.50) | -123450.0% |
| Fair Value | -83.43 - -83.43 | -83.43 | -117.90% |
| P/E | (111.80) - (140.16) | (128.90) | -127.7% |
| EV/EBITDA | (85.20) - (109.25) | (99.83) | -121.4% |
| EPV | (127.72) - (201.06) | (164.39) | -135.3% |
| DDM - Stable | (211.33) - (3,157.67) | (1,684.50) | -461.5% |
| DDM - Multi | (115.52) - (1,380.81) | (215.70) | -146.3% |
| Market Cap (mil) | 33,109.30 |
| Beta | 0.81 |
| Outstanding shares (mil) | 71.05 |
| Enterprise Value (mil) | 32,727.79 |
| Market risk premium | 5.10% |
| Cost of Equity | 7.00% |
| Cost of Debt | 7.48% |
| WACC | 7.01% |